Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents

Executive Summary

While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.

Advertisement

Related Content

Liver Cancer: What's Close To The Market
Safety Issues Not Dampening AbbVie Optimism For Humira Successors
Commercial Capsules: Q2 Reporters, Mitsubishi Buy, Celltrion IPO, Renflexis Launch, Keytruda Fail, Ironwood and Vertex Trial Results
2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead
ASCO Upsets CDK4/6 Class: Strong Data For Lilly's Abemaciclib, But Pfizer's Ibrance Disappoints
Lilly's Cyramza Expands Its RANGE With Bladder Cancer But OS Data Needed
Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?
Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099203

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel